cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1312Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMКомбинированная терапия артериальной гипертонии: фокус на плейотропные эффектыCombined therapy of arterial hypertension: focus on pleiotropic effectsНебиеридзеД. В.NebieridzeD. B.oganov@gnicpm.ruГосударственный научно-исследовательский центр профилактической медицины Росздрава, МоскваState Research Center for Preventive Medicine, State Federal Agency for Health and Social Development, Moscow2007200820076499102Copyright © Небиеридзе Д.В., 20072007Небиеридзе Д.В.Nebieridze D.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1312

В публикации подчеркивается значение не только адекватного контроля артериального давления (АД) при артериальной гипертонии, но и плейотропных эффектов лечения. Особенно это актуально для комбинированной терапии, которая в большинстве случаев позволяет достичь целевой уровень АД. Среди плейтропных эффектов важное значение имеют метаболические и возможность вазопротекции на основе улучшения эндотелиальной функции. Представлена уникальная комбинация препарата Тарка, компонентами которого являются два хорошо известных средства – верапамил в форме медленного высвобождения в дозе 180 мг и трандолаприла в дозе 2 мг. Тарка обеспечивает не только пролонгированный контроль АД, но и метаболически благоприятный профиль, вазопротекцию и органопротекцию.

The article is focused on the importance of adequate blood pressure (BP) control in arterial hypertension, as well as on pleiotropic treatment effects. The latter are especially important in combined therapy, that, as a rule, is needed to achieve target BP levels. The principal pleiotropic effects include metabolic action and vasoprotection via endothelial function improvement. Tarka medication includes two well-known agents - verapamil SR (180 mg) and trandolapril (2 mg). Tarka therapy facilitates not only prolonged BP control, but also vasoprotection and organ protection, without adverse metabolic effects.

артериальная гипертониякомбинированная терапияметаболические эффектывазо- и органопротекцияarterial hypertensioncombined therapymetabolic effectsvasoprotectionorgan protectionReferencesВторой пересмотр рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваск тер профил 2004; 3(3) ч.1: 105-20.Второй пересмотр рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваск тер профил 2004; 3(3) ч.1: 105-20.Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfined randomized drug trials in an epidemiological context. Lancet 1990; 335: 827-38.Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfined randomized drug trials in an epidemiological context. Lancet 1990; 335: 827-38.HOPE study investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.HOPE study investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.Estasio RO, Jeffers BW, Hiatt W, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ABCD Study. N Eng J Med 1998; 338: 645-52.Estasio RO, Jeffers BW, Hiatt W, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ABCD Study. N Eng J Med 1998; 338: 645-52.Kaplan M. Metabolic Aspects of Hypertension. Science press 1994, London.Kaplan M. Metabolic Aspects of Hypertension. Science press 1994, London.Pepine CJ, Handberg EM, Cooper RM, at al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Tretment Strategy for Patients With Coronary Artery Disease The International Verapamil SR/Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290(21): 2805-61.Pepine CJ, Handberg EM, Cooper RM, at al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Tretment Strategy for Patients With Coronary Artery Disease The International Verapamil SR/Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290(21): 2805-61.The ALLHAT Officers and Coordinators Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.The ALLHAT Officers and Coordinators Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension 2003. Guidelines Committee. J Hypertens 2003; 21: 1011-53.European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension 2003. Guidelines Committee. J Hypertens 2003; 21: 1011-53.Fernandez R, Puig JG, Rodrigues-Perez JC, et al. Effect of two antihypertensive combinations on metabolic control in type -2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Human Hypertens 2001; 15: 849-56.Fernandez R, Puig JG, Rodrigues-Perez JC, et al. Effect of two antihypertensive combinations on metabolic control in type -2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Human Hypertens 2001; 15: 849-56.Bakris G, Molitch M, Hewkin A, et al. Differences in Glucose tolerance between fixed dose Antihypertensive Drug Combinations in People with Metabolic Syndrome. Diabetes Care 2006; 29: 2592-7.Bakris G, Molitch M, Hewkin A, et al. Differences in Glucose tolerance between fixed dose Antihypertensive Drug Combinations in People with Metabolic Syndrome. Diabetes Care 2006; 29: 2592-7.Zanchetti A, Rosei EA, Palu CD, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.Zanchetti A, Rosei EA, Palu CD, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.Hansen JF, Hageruo L, Sigurd B. Cardiac Event Rates After Acute Myocardial Infarction in Patients Treated With Verapamil and Trandolapril Versus Trandolapril Alone, et al. Am J Cardiol 1997; 79: 738-41.Hansen JF, Hageruo L, Sigurd B. Cardiac Event Rates After Acute Myocardial Infarction in Patients Treated With Verapamil and Trandolapril Versus Trandolapril Alone, et al. Am J Cardiol 1997; 79: 738-41.Ruggenenti P, Fassi A, Parvanova Ilieva A, et al. Preventing microalbuminuria in Type 2 Diabetes. N Engl J Med 2004; 351: 1941-51.Ruggenenti P, Fassi A, Parvanova Ilieva A, et al. Preventing microalbuminuria in Type 2 Diabetes. N Engl J Med 2004; 351: 1941-51.

The authors declare that there are no conflicts of interest present.